PMID- 28733154
OWN - NLM
STAT- MEDLINE
DCOM- 20180514
LR  - 20181202
IS  - 1544-3450 (Electronic)
IS  - 1086-5802 (Linking)
VI  - 57
IP  - 5
DP  - 2017 Sep-Oct
TI  - Community pharmacists' knowledge of Alzheimer disease care in high- and 
      low-income Chicago.
PG  - 596-600.e1
LID - S1544-3191(17)30703-3 [pii]
LID - 10.1016/j.japh.2017.05.011 [doi]
AB  - OBJECTIVES: This pilot study examined community pharmacists' knowledge to provide 
      care and services for persons with Alzheimer disease (AD) and area income-based 
      disparities in knowledge and availability of cognitive enhancers. METHODS: A 
      cross-sectional telephone survey of pharmacies (n = 137) in high- and low-income 
      areas in Chicago was conducted on pharmacists' degree, experience, and continuing 
      education, as well as knowledge of AD disease and treatment expectations, adverse 
      effects (AEs) of donepezil, and self-care recommendations for insomnia. 
      Pharmacies were selected from highest- and lowest-income zip code areas, defined 
      using household area median incomes from the 2008-2012 American Community Survey 
      5-Year Estimates. In-stock availability of select cognitive enhancers was 
      obtained. Chi-square, Fisher exact test, and simple and multiple logistic 
      regression analyses were performed with the use of Stata 10.1. RESULTS: Odds were 
      70% lower that pharmacists in low-income areas would say there was nothing to 
      reverse the course of AD (odds ratio [OR] 0.30, 95% confidence interval [CI] 
      0.13-0.70) and 7 times greater that they would recommend a medication to reverse 
      the course of AD (OR 7.04, 95% CI 2.19-22.62) compared with pharmacists in 
      high-income areas. Odds were more than 50% lower that pharmacists in low-income 
      areas would name at least 1 adverse effect for donepezil (OR 0.42, 95% CI 
      0.19-0.92) compared with peers in high-income areas. Pharmacies in low-income 
      areas had lower odds of having 4 of the 5 surveyed formulations of cognitive 
      enhancers in stock. CONCLUSION: It is concerning that 20%-30% of pharmacists 
      recommended a medication to "reverse" the course of AD, about one-half of 
      pharmacists could not mention a single adverse effect of donepezil, and more than 
      one-fourth of pharmacists made an inappropriate self-care sleep aid 
      recommendation for a person with AD who was using rivastigmine patch. Although 
      overall results regarding pharmacists' knowledge were poor, performance was 
      significantly poorer in low-income areas. As our AD population increases, we need 
      to strengthen pharmacists' knowledge on and competencies important for 
      pharmacy-related AD care.
CI  - Copyright (c) 2017 American Pharmacists Association(R). Published by Elsevier Inc. 
      All rights reserved.
FAU - Marvanova, Marketa
AU  - Marvanova M
FAU - Henkel, Paul Jacob
AU  - Henkel PJ
LA  - eng
PT  - Journal Article
DEP - 20170718
PL  - United States
TA  - J Am Pharm Assoc (2003)
JT  - Journal of the American Pharmacists Association : JAPhA
JID - 101176252
RN  - 0 (Indans)
RN  - 0 (Nootropic Agents)
RN  - 0 (Piperidines)
RN  - 8SSC91326P (Donepezil)
SB  - IM
MH  - Alzheimer Disease/complications/*drug therapy
MH  - Chicago
MH  - Cross-Sectional Studies
MH  - Donepezil
MH  - Female
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - *Income
MH  - Indans/adverse effects/therapeutic use
MH  - Male
MH  - Nootropic Agents/adverse effects/therapeutic use
MH  - Pharmacists/*psychology
MH  - Pilot Projects
MH  - Piperidines/adverse effects/therapeutic use
MH  - Self Care
MH  - Sleep Initiation and Maintenance Disorders/complications/drug therapy
EDAT- 2017/07/25 06:00
MHDA- 2018/05/15 06:00
CRDT- 2017/07/23 06:00
PHST- 2016/12/06 00:00 [received]
PHST- 2017/05/15 00:00 [revised]
PHST- 2017/05/20 00:00 [accepted]
PHST- 2017/07/25 06:00 [pubmed]
PHST- 2018/05/15 06:00 [medline]
PHST- 2017/07/23 06:00 [entrez]
AID - S1544-3191(17)30703-3 [pii]
AID - 10.1016/j.japh.2017.05.011 [doi]
PST - ppublish
SO  - J Am Pharm Assoc (2003). 2017 Sep-Oct;57(5):596-600.e1. doi: 
      10.1016/j.japh.2017.05.011. Epub 2017 Jul 18.